Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05555550
EARLY_PHASE1

Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

Sponsor: Children's Hospital of Philadelphia

View on ClinicalTrials.gov

Summary

The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with Low Grade Gliomas (LGG). Imaging with 18F-Fluciclovine PET-MRI will be performed prior to initiation of therapy for LGG, and then 3 months, and 1 year after starting therapy. Changes in 18F-Fluciclovine uptake will be compared to changes in MRI measurements at 3 months and 1 year as compared to baseline.

Official title: Evaluation of 18F-Fluciclovine PET-MRI as a Biomarker of Response in Pediatric and Young Adult Patients With Low Grade Gliomas (LGG)

Key Details

Gender

All

Age Range

1 Year - 21 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2025-12-29

Completion Date

2027-09

Last Updated

2025-12-04

Healthy Volunteers

No

Interventions

DRUG

18F-Fluciclovine

18F-Fluciclovine will be injected via IV prior to PET-MRI imaging

Locations (1)

The Children s Hospital of Philadelphia

Philadelphia, Pennsylvania, United States